pharma · Hypercholesterolemia · Hyperlipidemia · ESPR
Esperion Therapeutics
Esperion Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Ann Arbor, US
- Employees
- 5
- Programs
- 15
- Drugs
- 9
- Patents
- 55
Esperion Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Esperion Therapeutics.
Esperion Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bempedoic acid + Ezetimibe FDC Oral Tablet
Esperion Therapeutics
Diabetes
1 trial -
Bempedoic acid 180mg
Esperion Therapeutics
Hypercholesterolemia
2 trials -
Bempedoic acid, bempedoic acid
Esperion Therapeutics
Heterozygous familial hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
1 trial -
ETC-1002
Esperion Therapeutics
Dyslipidemia
1 trial -
ETC-1002
Esperion Therapeutics
Hyperlipidemia
2 trials
Frequently asked questions
How many clinical projects does Esperion Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.